NCT03324425: Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

NCT03324425
Breast Cancer Type: HER2++
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled unstable CNS metastatic disease- see trial for details
https://ClinicalTrials.gov/show/NCT03324425

Comments are closed.

Up ↑